Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

Next Previous
Trial Profile

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IAM 1363 (Primary) ; Trastuzumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Brain metastases; Cancer; Colorectal cancer; Male breast cancer; Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Iambic Therapeutics

Most Recent Events

  • 04 Jun 2025 According to an Iambic Therapeutics media release, the company has completed dose escalation in IAM1363-01 trial and plans to share initial study data at ESMO Congress in October 2025. Patients now enrolling into dose optimization include those with HER2-altered cancers and brain metastases, any advanced cancer harboring a HER2 TKD (tyrosine kinase domain) mutation, and advanced HER2-amplified NSCLC. The study, which has multiple sites in the US, will expand to the EU, UK and APAC.
  • 06 Jan 2025 According to an Iambic Therapeutics media release, company anticipate data from this study in 2025.
  • 27 Dec 2024 Primary endpoints has been amended.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top